| NCT ID | NCT06926010 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
| Condition | Carotid Artery Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-04-10 |
| Primary Completion | 2026-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2025-04-10 with a primary completion date of 2026-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
patients scheduled for carotid endoarterectomy will be randomly assigned to a group in which arterial hypotension will be avoided by a predictive haemodynamic approach or to a group in which arterial hypotension will be treated in a standard manner
Eligibility Criteria
Inclusion Criteria: \- \>18 years old patients Exclusion Criteria: * Body MassIndex \> 35 Kg /m2; * Atrial Fibrillation * Urgent surgery * Pregnancy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06926010 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Carotid Artery Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06926010 currently recruiting?
Yes, NCT06926010 is actively recruiting participants. Contact the research team at andrea.russo@policlinicogemelli.it for enrollment information.
Where is the NCT06926010 trial being conducted?
This trial is being conducted at Rome, Italy.
Who is sponsoring the NCT06926010 clinical trial?
NCT06926010 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The trial plans to enroll 120 participants.